These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 7517275)

  • 41. [Trial of intracavernous papaverine in the treatment of impotence. Therapeutic prospects].
    Virag R; Virag H
    J Mal Vasc; 1983; 8(4):293-5. PubMed ID: 6663198
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Intracavernous self-injection of papaverine and regitine for the treatment of organic impotence.
    Janosko EO
    N C Med J; 1986 Jun; 47(6):305-7. PubMed ID: 3461285
    [No Abstract]   [Full Text] [Related]  

  • 43. Comparison of the efficacy and safety of sildenafil citrate (Viagra) and oral phentolamine for the treatment of erectile dysfunction.
    Ugarte F; Hurtado-Coll A
    Int J Impot Res; 2002 Aug; 14 Suppl 2():S48-53. PubMed ID: 12161768
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Effectiveness and safety of multidrug intracavernous therapy for vasculogenic impotence.
    Montorsi F; Guazzoni G; Bergamaschi F; Dodesini A; Rigatti P; Pizzini G; Miani A
    Urology; 1993 Nov; 42(5):554-8. PubMed ID: 7694416
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Penile function following intracavernosal injection of vasoactive agents or saline.
    Kiely EA; Ignotus P; Williams G
    Br J Urol; 1987 May; 59(5):473-6. PubMed ID: 3594105
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Long-term intracavernous therapy responders can potentially switch to sildenafil citrate after radical prostatectomy.
    Raina R; Lakin MM; Agarwal A; Ausmundson S; Montague DK; Zippe CD
    Urology; 2004 Mar; 63(3):532-7; discussion 538. PubMed ID: 15028452
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Evaluation of 452 patients with erectile dysfunction treated by combinations of vasoactive agents by penile injection].
    Segenreich E; Israilov S; Shmueli J; Simon D; Baniel J; Livne P
    Harefuah; 1998 May; 134(9):673-8, 750. PubMed ID: 10909609
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Comparative study of papaverine plus phentolamine versus prostaglandin E1 in erectile dysfunction.
    Bechara A; Casabé A; Chéliz G; Romano S; Rey H; Fredotovich N
    J Urol; 1997 Jun; 157(6):2132-4. PubMed ID: 9146599
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Effect of phentolamine on venous return in human erection.
    Wespes E; Rondeux C; Schulman CC
    Br J Urol; 1989 Jan; 63(1):95-7. PubMed ID: 2920269
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Intracavernous pharmacotherapy in psychogenic impotence.
    Weiss JN; Ravalli R; Badlani GH
    Urology; 1991 May; 37(5):441-3. PubMed ID: 1708925
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Treatment of persistent penile erection and priapism using terbutaline.
    Shantha TR; Finnerty DP; Rodriquez AP
    J Urol; 1989 Jun; 141(6):1427-9. PubMed ID: 2724442
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Evaluation of electromyography of the corpora cavernosa (single potential analysis of cavernous electric activity--SPACE) as a technique for studying impotence].
    Salinas Casado J; Vírseda Chamorro M; Samblas García R; Esteban Fuertes M; Aristizábal Agudelo JM; Blázquez Izquierdo J; Delgado Martín JA; Resel Estévez L
    Arch Esp Urol; 1997 Jun; 50(5):512-9. PubMed ID: 9382594
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Vascular insufficiency: a significant factor in impotence.
    Zorgniotti AW
    N Y State J Med; 1989 Nov; 89(11):614-7. PubMed ID: 2626225
    [No Abstract]   [Full Text] [Related]  

  • 54. Treatment of male impotence--a pharmacologic erection program.
    Sanfelippo CJ; Deason AM; Tully AJ; Dennis RL; Leitner WA; Spivey C; Morgan C; Holmes B; Russell RT
    Ala Med; 1988 May; 57(11):17-9. PubMed ID: 3389297
    [No Abstract]   [Full Text] [Related]  

  • 55. Effects of oral phentolamine, taken before sleep, on nocturnal erectile activity: a double-blind, placebo-controlled, crossover study.
    Hatzichristou DG; Apostolidis A; Tzortzis V; Hatzimouratidis K; Kouvelas D
    Int J Impot Res; 2001 Oct; 13(5):303-8. PubMed ID: 11890519
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [A program of intracavernous drug-induced erection for the treatment of impotence].
    Navío S; Allona A; Serrano A; Vallejo J; del Hoyo J; Rivas JA; Escudero A
    Actas Urol Esp; 1993 Jan; 17(1):62-7. PubMed ID: 8452086
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The use of a vacuum constrictor device to augment a partial erection following an intracavernous injection.
    Marmar JL; DeBenedictis TJ; Praiss DE
    J Urol; 1988 Nov; 140(5):975-9. PubMed ID: 3172371
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Hemodynamics of penile erection: III. Measurement of deep intracavernosal and subtunical blood flow and oxygen tension.
    Azadzoi KM; Vlachiotis J; Pontari M; Siroky MB
    J Urol; 1995 Feb; 153(2):521-6. PubMed ID: 7815637
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Cytotoxicity of different intracavernous vasoactive drugs on cultured endothelial cells of human corpus cavernosum penis.
    Schultheiss D; Pilatz A; Gabouev AI; Schlote N; Wefer J; Mertsching H; Sohn M; Jonas U; Stief CG
    Urology; 2004 Sep; 64(3):598-602. PubMed ID: 15351616
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Prostaglandin E1 versus mixture of prostaglandin E1, papaverine and phentolamine in nonresponders to high papaverine plus phentolamine doses.
    Bechara A; Casabé A; Chéliz G; Romano S; Fredotovich N
    J Urol; 1996 Mar; 155(3):913-4. PubMed ID: 8583605
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.